| Nesina (alogliptin) / Takeda |
NCT01303055: Effects of Alogliptin on Pancreatic Beta Cell Function |
|
|
| Unknown status | N/A | 80 | Japan | Alogliptin, Nothing, Metformin 750 mg | Aichi Gakuin University | Diabetes Mellitus, Type 2 | 12/13 | 12/14 | | |
NCT01945242: Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones" |
|
|
| Completed | N/A | 1374 | Japan | Alogliptin, Nesina; SYR-322 | Takeda | Type 2 Diabetes Melitus | 06/14 | 06/14 | | |
NCT01964976: Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides |
|
|
| Completed | N/A | 1096 | Japan | | Takeda | Surveillance | 12/14 | 12/14 | | |
NCT01964950: Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea |
|
|
| Completed | N/A | 1101 | Japan | | Takeda | Surveillance | 12/14 | 12/14 | | |
NCT02798172: The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy |
|
|
| Completed | N/A | 81 | RoW | Alogliptin and Metformin | Fourth People's Hospital of Shenyang | Diabetes Mellitus, Type 2 | 08/15 | 08/15 | | |
NCT01945216: Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI" |
|
|
| Completed | N/A | 3317 | Japan | Alogliptin, Nesina; SYR-322 | Takeda | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | 10/15 | 10/15 | | |
ChiCTR-IOR-16008717: RANDOMIZED, OPEN-LABEL, 2-PEROID CROSSOVER BIOEQUIVALENCE STUDY OF ALOGLIPTIN BENZOATE TABLET AND IN CHINESE HEALTHY SUBJECTS UNDER FASTING/POSTPRANDIAL CONDITIONS |
|
|
| Not yet recruiting | N/A | 56 | | diet, treatment | First Hospital of Jilin University; Yabao Pharmaceutical Group Co., Ltd, provided by Yabao Pharmaceutical Group Co.,Ltd | T2DM | | | | |
NCT02221284: Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)" |
|
|
| Completed | N/A | 964 | Japan | Alogliptin, Nesina Tablets | Takeda | Type 2 Diabetes Mellitus | 06/17 | 06/17 | | |
NCT01964963: Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus |
|
|
| Completed | N/A | 19192 | Japan | Alogliptin, Nesina, SYR-322 | Takeda | Type 2 Diabetes Mellitus | 07/17 | 07/17 | | |
NCT01588587: DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients |
|
|
| Unknown status | N/A | 500 | Japan | Sitagliptin, Other names are not known., Alogliptin, Vildagliptin, Other name is not known. | Nagaoka Red Cross Hospital, Kurume University | Type 2 Diabetes Mellitus | 10/17 | 12/17 | | |
ChiCTR-OOC-16008298: influence of Alogliptin on the degree of daytime sleepiness in patients with type 2 diabetes mellitus |
|
|
| Not yet recruiting | N/A | 20 | | placebo with metformin ;Alogliptin with metformin | Peking University First Hospital; Peking University First Hospital, Offered by China International Medical Foundation | daytime sleepness | | | | |
NCT02989649: Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice |
|
|
| Terminated | N/A | 593 | RoW | Alogliptin, Alogliptin FDC With Pioglitazone, Alogliptin FDC With Metformin | Takeda | Diabetes Mellitus, Type 2 | 01/18 | 01/18 | | |
NCT02756832: An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2 |
|
|
| Completed | N/A | 1409 | RoW | Alogliptin Benzoate, VIPIDIA® | Takeda | Diabetes Mellitus | 04/18 | 04/18 | | |
NCT04980040: A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea |
|
|
| Completed | N/A | 3623 | RoW | Alogliptin Benzoate, Nesina® Tablet | Takeda | Type 2 Diabetes Mellitus | 08/19 | 08/19 | | |
| Completed | N/A | 241981 | US | SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) | Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute | Type 2 Diabetes Mellitus, Cardiovascular Diseases | 12/24 | 03/25 | | |
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
|
|
| Active, not recruiting | N/A | 781430 | US | SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University | Cardiovascular Events, Type2 Diabetes, Renal Disease | 01/26 | 07/26 | | |
